0
0
10/11/23 at 11:22am
Organization
Targetedonc.com
Author
Sabrina Serani
36 words
0
Comments
In a phase 2 trial, BXCL701 and pembrolizumab showed a significant increase in median overall survival time for patients with small cell neuroendocrine prostate cancer.
You are the first to view
https://www.targetedonc.com/view/bxcl701-and-pembrolizumab-combo-delivers-os-improvements-in-scnc
Create an account
or login to join the discussion